Krystal Biotech, Inc. (KRYS) Earnings
Krystal Biotech, Inc. is expected to report next earnings on August 3, 2026 (in NaN days), with a consensus EPS estimate of $1.81. KRYS has beaten EPS estimates in 9 of its last 12 reported quarters (average surprise +14.8% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $1.45 | $1.83 | +26.2% | $116M | +3.8% |
| Feb 17, 2026 | $1.62 | $1.70 | +4.9% | $107M | -5.7% |
| Feb 19, 2025 | $1.29 | $1.52 | +17.8% | $91M | -0.2% |
| Feb 27, 2023 | $-1.39 | $-1.25 | +10.1% | — | — |
| Feb 28, 2022 | $-0.76 | $-0.94 | -23.7% | — | — |
| Mar 1, 2021 | $-0.55 | $-0.53 | +3.6% | — | — |
| May 4, 2020 | $-0.42 | $-0.31 | +26.2% | — | — |
| Mar 10, 2020 | $-0.33 | $-0.31 | +6.1% | — | — |
| May 7, 2019 | $-0.35 | $-0.29 | +17.1% | $583000 | -12.1% |
| Mar 12, 2019 | $-0.24 | $-0.28 | -16.7% | $1M | +135.9% |
| Nov 5, 2018 | $-0.25 | $-0.26 | -4.0% | $217000 | +0.5% |
| Aug 6, 2018 | $-0.26 | $-0.22 | +15.4% | $173000 | -35.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 4, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Good morning, Krish mentioned it's been 10 years since Crystal was founded. Vizuvac delivered global revenue growth, with 9% sequential growth vs 4Q2025. Outside the US, progress in Europe and Japan was noted. FDA granted platform technology designations to KB407 for CF and KB111 for Haley-Haley. Laurent discussed the international launch of Vizuvac in key markets. Christine updated on the US launch, highlighting over 695 reimbursement approvals and new prescribers. Suma shared that there are two registrational readouts expected later this year and two more in 2027, with progress on various clinical pipelines.
Guidance
Anticipates two registrational readouts this year and two more in 2027. Looks forward to data readouts from the pipeline, including for eye registrations, repeat dose data from KB407 and KB111, and updates from other pipeline programs like KB707 and KB408.
Segment performance
Vizuvac achieved global net revenue of $116.4 million in the quarter, with cumulative net Vizuvac revenue since launch surpassing $846 million. In the US, net revenue was $87.5 million for the quarter. Outside the US, Europe and Japan contributed $28.9 million in net revenue. Gross margin stood at 95%.
Analyst Q&A
Q: Roger Song asked about the commercial growth trajectory and the CF pipeline.
A: Krish talked about the global trajectory of the launch, noting country-level fluctuations but overall positive outlook. Suman discussed the CF trial design, including the interim five-patient study to establish safety in repeat-dose administration and ongoing discussions with the FDA and CFF Foundation on the registrational trial design.
Q: Alec Stranahan asked about KB803 launch potential and Haley-Haley data.
A: Answered on KB803 launch potential, expecting a positive trajectory given identified patients and ironed-out launch kinks. For Haley-Haley, discussed the phase one study to validate the severity scale and collect safety and dosing regimen data, with registration trial expected in 2027.
Q: Joe Pangenius asked about education and negotiations in ex-US markets.
A: Krish and Christine answered on ex-US physician education being easier due to awareness from US launch, and negotiations involving political factors and budget for rare diseases, with benchmarks in Germany and Italy.
Q: Ritu Baral asked about insurance dynamics and CF patient subpopulations.
A: Answered that there have been no access issues with start and stop effect, and on CF, noted patients include those not tolerating or not benefiting from modulators, with discussion on sweat chloride and repeat dose data needs.
Q: Yigal Natramovitz asked about Europe progress and KB803.
A: Answered on Europe progress with entry into second six months of launch in Germany and ongoing negotiations in Spain, and on KB803, discussed the blinded trial setup and data collection from natural history study.
Q: Bill Mahan asked about KB803 powering and capital allocation.
A: Answered on KB803 being powered to detect a 25% reduction in symptom days, leveraging natural history data, and on capital allocation, stating no plans for licensing or buying, focusing on growth in commercial and pipeline.
Q: Gavin Clark asked about KB803 baseline and powering.
A: Answered that the study was powered based on natural history data, selecting patients meeting criteria to see drug effect, and using crossover design to improve sample size.
Q: Joshua Soto asked about US home admin impact and ex-US Spain.
A: Answered that home administration label updates have positively impacted US launch, with patients having more flexibility. On ex-US Spain, noted pricing within corridor and similar patient prevalence to other European territories